How India Exports Ranitidine to the World

Ranitidine has been a widely used medication in the United States, with numerous Abbreviated New Drug Applications (ANDAs) approved by the FDA. For instance, Geneva Pharmaceuticals received approval for ANDA #074467 on August 29, 1997, and Glaxo Wellcome Inc. obtained approval for NDA #020745 on February 26, 1998.

However, in April 2020, the FDA requested the removal of all ranitidine products from the U.S. market due to the detection of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in these products. This action led to a significant regulatory shift, impacting the 248 active Indian exporters supplying ranitidine to the U.S. market. The regulatory pathway for re-entry into the U.S. market now requires comprehensive data demonstrating the absence of NDMA impurities and adherence to stringent quality standards.

In the European Union, the European Medicines Agency (EMA) initiated a review of ranitidine medicines in September 2019 following the detection of NDMA impurities. By April 2020, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the suspension of all ranitidine medicines in the EU. This suspension was confirmed in November 2020, leading to the withdrawal of marketing authorizations across member states. (ema.europa.eu)

Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a supply disruption alert in October 2019, instructing manufacturers to quarantine all ranitidine products due to NDMA contamination concerns. This action effectively removed ranitidine from the UK market, aligning with the EU's precautionary measures. (cas.mhra.gov.uk)

Ranitidine was included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its importance in treating gastrointestinal conditions. However, following the detection of NDMA impurities, the WHO issued safety alerts regarding ranitidine, advising regulatory authorities to assess the risk and consider appropriate actions. (who.int)

Pharmacopoeial standards, including those from the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), have historically included monographs for ranitidine. In light of contamination concerns, these standards are under review to ensure the quality and safety of ranitidine products.

In India, ranitidine is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The Central Drugs Standard Control Organization (CDSCO) oversees its regulation. Following global concerns about NDMA impurities, the CDSCO issued advisories to pharmaceutical companies to assess and ensure the quality of ranitidine products.

The National Pharmaceutical Pricing Authority (NPPA) had set ceiling prices for ranitidine formulations under the Drug Price Control Order (DPCO). However, due to safety concerns and subsequent market withdrawals, these pricing controls are subject to review. Export No Objection Certificates (NOCs) are required for the export of ranitidine, ensuring compliance with both domestic and international regulatory standards.

The primary patents for ranitidine have long expired, leading to a competitive generic market. However, the detection of NDMA impurities has led to market withdrawals and increased scrutiny, affecting the competitive landscape. Manufacturers must now demonstrate compliance with updated safety and quality standards to re-enter markets.

In April 2020, the FDA requested the removal of all ranitidine products from the U.S. market due to NDMA contamination, leading to a significant shift in the regulatory landscape. (ema.europa.eu)

In November 2020, the EMA confirmed the suspension of all ranitidine medicines in the EU, reinforcing the global trend of regulatory actions against ranitidine due to safety concerns. (ema.europa.eu)

In October 2019, the UK's MHRA issued a supply disruption alert, instructing manufacturers to quarantine all ranitidine products, effectively removing them from the UK market. (cas.mhra.gov.uk)

In April 2020, the WHO issued an information note updating on nitrosamine impurities, including those found in ranitidine, advising regulatory authorities to assess risks and consider appropriate actions. (tdr.who.int)

These developments underscore the heightened regulatory scrutiny and the need for manufacturers to ensure the safety and quality of ranitidine products in compliance with international standards.

Ranitidine's production heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with a significant portion sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of intermediates, making it a dominant player in the pharmaceutical raw material market. This dependency exposes the supply chain to risks associated with China's regulatory changes and environmental policies. For instance, over the past five years, numerous Chinese API manufacturers have been shut down due to non-compliance with pollution norms, leading to supply disruptions and cost escalations.

In response to these challenges, India has initiated measures to reduce its reliance on Chinese imports. The Production Linked Incentive (PLI) scheme, launched in 2020, aims to bolster domestic API manufacturing by providing financial incentives to local producers. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics, marking a significant step towards self-reliance. However, the effectiveness of these initiatives in mitigating supply chain risks for ranitidine remains to be fully realized.

Our proprietary trade data indicates that the top five Indian exporters of ranitidine account for 54.2% of the total export value, with COMBITIC GLOBAL CAPLET PRIVATE LIMITED leading at a 21.4% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges. The PLI scheme's focus on enhancing domestic API production is a strategic move to diversify the supplier base and reduce single-source dependency. However, the transition to a more diversified supply chain will require time and sustained effort.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt supply chains. Additionally, trade disputes, such as those between the U.S. and China, have led to increased tariffs and export restrictions, impacting the availability and cost of pharmaceutical raw materials. The U.S. Food and Drug Administration (FDA) has issued alerts regarding drug shortages, highlighting the vulnerability of the pharmaceutical supply chain to such disruptions. These factors underscore the need for robust risk mitigation strategies in the ranitidine supply chain.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to strengthen local manufacturing capabilities for APIs and KSMs.

• Monitor Regulatory Compliance: Regularly assess suppliers' adherence to environmental and quality standards to anticipate potential disruptions.

• Develop Contingency Plans: Establish alternative logistics and shipping routes to mitigate the impact of geopolitical tensions on supply chains.

• Invest in Supply Chain Transparency: Implement technologies that provide real-time visibility into the supply chain to identify and address risks proactively.

RISK_LEVEL: MEDIUM